OSA
MCID: APN008
MIFTS: 66

Apnea, Obstructive Sleep (OSA)

Categories: Blood diseases, Mental diseases, Respiratory diseases

Aliases & Classifications for Apnea, Obstructive Sleep

MalaCards integrated aliases for Apnea, Obstructive Sleep:

Name: Apnea, Obstructive Sleep 57
Obstructive Sleep Apnea Syndrome 57 12 43 29 6 15
Obstructive Sleep Apnea 12 73 43 15 62 17
Sleep Apnea, Obstructive 43 44 70
Upper Airway Resistance Sleep Apnea Syndrome 43 70
Sleep Apnea/hypopnea Syndrome 57 43
Osas 57 43
Sahs 57 43
Osa 57 43
Sleep Apnea/hypopnea Syndrome; Sahs; Osahs 57
Obstructive Sleep Apnea Syndrome; Osas 57
Sleep Apnea Syndrome, Obstructive 43
Sleep Apnea Hypopnea Syndrome 43
Sleep Apnea Obstructive 54
Sleep Apnea Syndromes 70
Apnea, Obstructive 43
Obstructive Apnea 43
Osahs 43

Characteristics:

OMIM®:

57 (Updated 20-May-2021)
Inheritance:
autosomal dominant


HPO:

31
apnea, obstructive sleep:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:0050848
OMIM® 57 107650
ICD9CM 34 327.23
MeSH 44 D020181
NCIt 50 C116337
SNOMED-CT 67 194441007
ICD10 32 G47.33
MedGen 41 C0520679
UMLS 70 C0037315 C0520679 C0751761

Summaries for Apnea, Obstructive Sleep

MedlinePlus Genetics : 43 Obstructive sleep apnea is a condition in which individuals experience pauses in breathing (apnea) during sleep, which are associated with partial or complete closure of the throat (pper airway). Complete closure can lead to apnea while partial closure allows breathing but decrease the intake of oxygen (hypopnea).Individuals with obstructive sleep apnea may experience interrupted sleep with frequent awakenings and loud snoring. Repeated pauses in breathing lead to episodes of lower-than-normal oxygen levels (hypoxemia) and a buildup of carbon dioxide (hypercapnia) in the bloodstream. Interrupted and poor quality sleep can lead to daytime sleepiness and fatigue, impaired attention and memory, headaches, depression, and sexual dysfunction. Daytime sleepiness leads to a higher risk of motor vehicle accidents in individuals with obstructive sleep apnea. Obstructive sleep apnea is also associated with an increased risk of developing insulin resistance, which is an inability to regulate blood sugar levels effectively; high blood pressure (hypertension); heart disease; and stroke.

MalaCards based summary : Apnea, Obstructive Sleep, also known as obstructive sleep apnea syndrome, is related to obesity-hypoventilation syndrome and focal segmental glomerulosclerosis, and has symptoms including seizures, tremor and back pain. An important gene associated with Apnea, Obstructive Sleep is LEP (Leptin), and among its related pathways/superpathways are Signaling by GPCR and Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.. The drugs Phenylephrine and Zopiclone have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and tongue, and related phenotypes are anosmia and focal impaired awareness seizure

Disease Ontology : 12 A sleep apnea that is characterized by repeated collapse and obstruction of the upper airway during sleep, which results in reduced airflow (hypopnea) or complete airflow cessation (apnea), oxygen desaturation, and arousals from sleep.

OMIM® : 57 Obstructive sleep apnea is a common, chronic, complex disease associated with serious cardiovascular and neuropsychologic sequelae and with substantial social and economic costs (Palmer et al., 2003). (107650) (Updated 20-May-2021)

PubMed Health : 62 About obstructive sleep apnea: We all know what it is like to feel tired after a sleepless night because of things like noise, worries or stress. But what if you do actually get enough sleep and still feel absolutely beat the next morning? This is normal for many people with obstructive sleep apnea (OSA): They do not get enough air while they are sleeping (but do not usually notice this), have breathing pauses, and feel very sleepy during the day. In the long term, this increases their risk of developing other illnesses and can have a huge effect on their quality of life.

Wikipedia : 73 Obstructive sleep apnea (OSA) is the most common sleep-related breathing disorder and is characterized... more...

Related Diseases for Apnea, Obstructive Sleep

Diseases related to Apnea, Obstructive Sleep via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1417)
# Related Disease Score Top Affiliating Genes
1 obesity-hypoventilation syndrome 32.2 LEP IL6 ADIPOQ
2 focal segmental glomerulosclerosis 32.0 TNF IL6 EDN1 ALB AGT ACE
3 gestational diabetes 31.3 TNF LEP INS IL6 CRP ADIPOQ
4 acromegaly 31.3 LEP INS IGF1 GHRL ADIPOQ
5 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 31.2 LEP INS ADIPOQ
6 hypercholesterolemia, familial, 1 31.2 INS CRP APOE ACE
7 aortic disease 31.1 REN IL6 CRP ACE
8 sarcoidosis 1 31.0 TNF IL1B CRP ACE
9 nonarteritic anterior ischemic optic neuropathy 30.9 EDN1 CRP AGT ACE
10 mitral valve insufficiency 30.9 REN CRP ALB ACE
11 diabetic autonomic neuropathy 30.9 REN INS ACE
12 proteinuria, chronic benign 30.9 REN INS ALB ACE
13 peripheral vascular disease 30.9 IL6 HTR2A CRP ALB ACE
14 hydrocephalus 30.9 TNF IGF1 APOE ACE
15 esophagitis 30.9 TNF IL6 IL1B CXCL8
16 angina pectoris 30.9 INS IL6 EDN1 CRP ADIPOQ ACE
17 eclampsia 30.9 TNF REN EDN1 ALB AGT ACE
18 hernia, hiatus 30.9 GHRL CRP ADIPOQ
19 cardiogenic shock 30.9 TNF IL6
20 normal pressure hydrocephalus 30.9 IGF1 HCRT APOE ACE
21 diabetic macular edema 30.9 REN IL6 HIF1A
22 polycystic ovary syndrome 30.9 LEP INS IGF1 GHRL ADIPOQ
23 brain injury 30.8 IL6 IL1B IGF1 APOE ALB
24 diabetic neuropathy 30.8 REN LEP INS ACE
25 periodontitis, chronic 30.8 IL6 IL1B
26 intracranial hypertension 30.8 TNF IL1B ADIPOQ
27 tricuspid valve insufficiency 30.8 REN EDN1 CRP ALB ACE
28 familial partial lipodystrophy 30.8 TNF LEP INS ADIPOQ
29 eating disorder 30.8 LEP HTR2A HCRT GHRL ALB ADIPOQ
30 adult respiratory distress syndrome 30.8 TNF IL6 IL1B CXCL8 ACE
31 post-traumatic stress disorder 30.8 IL1B HTR2A CRP APOE ADIPOQ
32 idiopathic edema 30.8 INS EDN1 ADIPOQ ACE
33 dysthymic disorder 30.7 INS IL6 HTR2A HCRT CRP
34 amenorrhea 30.7 LEP INS IGF1 GHRL
35 sexual disorder 30.7 REN INS IGF1 HTR2A EDN1 ALB
36 hypertrophic cardiomyopathy 30.7 TNF REN IL6 IGF1 EDN1 ALB
37 microvascular complications of diabetes 3 30.7 REN INS ALB ACE
38 pleural empyema 30.7 IL6 CRP ALB
39 carotid artery disease 30.7 REN CRP APOE ACE
40 autoimmune disease 30.7 TNF INS IL6 IL1B CXCL8 CRP
41 hepatic encephalopathy 30.7 TNF IL6 ALB
42 homocysteinemia 30.7 CRP APOE ALB
43 hypothalamic obesity 30.6 LEP INS IGF1
44 patent foramen ovale 30.6 REN EDN1 CRP ALB ACE
45 varicose veins 30.6 TNF IL6 HIF1A CXCL8
46 vascular dementia 30.6 TNF IL6 IL1B IGF1 CRP APOE
47 chronic thromboembolic pulmonary hypertension 30.6 EDN1 CRP
48 lipodystrophy, familial partial, type 2 30.6 LEP INS ADIPOQ
49 acanthosis nigricans 30.6 LEP INS IGF1 ADIPOQ
50 hyperandrogenism 30.6 INS IGF1 ADIPOQ

Graphical network of the top 20 diseases related to Apnea, Obstructive Sleep:



Diseases related to Apnea, Obstructive Sleep

Symptoms & Phenotypes for Apnea, Obstructive Sleep

Human phenotypes related to Apnea, Obstructive Sleep:

31
# Description HPO Frequency HPO Source Accession
1 anosmia 31 HP:0000458
2 focal impaired awareness seizure 31 HP:0002384
3 obstructive sleep apnea 31 HP:0002870
4 excessive daytime somnolence 31 HP:0001262
5 snoring 31 HP:0025267

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
Neuro:
anosmia
partial complex seizures

Misc:
hypersomnolence
restless movements during sleep

Resp:
obstructive sleep apnea
snoring

Clinical features from OMIM®:

107650 (Updated 20-May-2021)

UMLS symptoms related to Apnea, Obstructive Sleep:


seizures; tremor; back pain; dyspnea; apnea; headache; syncope; excessive daytime somnolence; pain; wheezing; chronic pain; sciatica; snoring; sleep disturbances; cheyne-stokes respiration; coughing; vertigo/dizziness; sleeplessness; labored breathing; insomnia with sleep apnea, unspecified; hypersomnia with sleep apnea, unspecified; disruption of 24 hour sleep wake cycle, unspecified

MGI Mouse Phenotypes related to Apnea, Obstructive Sleep:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.44 ACE ADIPOQ AGT ALB APOE CRP
2 homeostasis/metabolism MP:0005376 10.41 ACE ADIPOQ AGT ALB APOE CRP
3 behavior/neurological MP:0005386 10.36 ACE ADIPOQ AGT APOE GHRL HCRT
4 growth/size/body region MP:0005378 10.34 ACE ADIPOQ AGT APOE EDN1 HCRT
5 immune system MP:0005387 10.33 ACE ADIPOQ AGT ALB APOE CRP
6 endocrine/exocrine gland MP:0005379 10.32 ACE ADIPOQ ALB APOE EDN1 GHRL
7 adipose tissue MP:0005375 10.26 ACE ADIPOQ AGT APOE GHRL IGF1
8 mortality/aging MP:0010768 10.25 ACE ADIPOQ AGT ALB APOE EDN1
9 digestive/alimentary MP:0005381 10.22 ALB APOE EDN1 GHRL HIF1A HTR2A
10 muscle MP:0005369 10.21 ADIPOQ AGT ALB APOE EDN1 HCRT
11 liver/biliary system MP:0005370 10.17 ACE ADIPOQ AGT ALB APOE HIF1A
12 nervous system MP:0003631 10.1 ACE ADIPOQ AGT APOE EDN1 HCRT
13 neoplasm MP:0002006 9.97 ACE ADIPOQ ALB HIF1A IGF1 IL1B
14 renal/urinary system MP:0005367 9.93 ACE ADIPOQ AGT ALB APOE EDN1
15 respiratory system MP:0005388 9.56 ADIPOQ APOE HCRT HIF1A IGF1 IL6
16 skeleton MP:0005390 9.36 ADIPOQ APOE EDN1 HIF1A HTR2A IGF1

Drugs & Therapeutics for Apnea, Obstructive Sleep

PubMed Health treatment related to Apnea, Obstructive Sleep: 62

If you are very overweight , losing weight can help improve sleep apnea . There are also many treatment options that aim to relieve sleep apnea. These include machines that support breathing during the night, surgery , and special aids such as mouth guards. Some of these treatments have been scientifically proven to help people with sleep apnea. Medication is currently not used for the treatment of sleep apnea. There is no scientific evidence that the available medications work. The most effective treatment for severe sleep apnea is called CPAP therapy . CPAP stands for “continuous positive airway pressure.” In this treatment approach, air is taken from the immediate surroundings and blown into your airways at night using low pressure. While you sleep, you wear a breathing mask that is connected to a machine called a respirator. The pressure keeps the upper airways open. People who use this machine have fewer breathing pauses, or even none at all. This can noticeably improve the symptoms such as tiredness during the day. Common side effects include a dry throat and an irritated, sometimes blocked nose .

Drugs for Apnea, Obstructive Sleep (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 397)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Phenylephrine Approved Phase 4 59-42-7 6041
2
Zopiclone Approved Phase 4 43200-80-2 5735
3
Opium Approved, Illicit Phase 4 8008-60-4
4
Budesonide Approved Phase 4 51333-22-3 63006 5281004
5
Adalimumab Approved, Experimental Phase 4 331731-18-1 16219006
6
Sodium citrate Approved, Investigational Phase 4 68-04-2
7
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
8
Ephedrine Approved Phase 4 299-42-3 9294
9
Pseudoephedrine Approved Phase 4 90-82-4 7028
10
Nitric Oxide Approved Phase 4 10102-43-9 145068
11
Xylometazoline Approved, Investigational Phase 4 526-36-3 5709
12
Remifentanil Approved Phase 4 132875-61-7 60815
13
Sodium oxybate Approved Phase 4 502-85-2 5360545
14
Desflurane Approved Phase 4 57041-67-5 42113
15
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
16
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
17
Donepezil Approved Phase 4 120014-06-4 3152
18
Sibutramine Approved, Illicit, Investigational, Withdrawn Phase 4 106650-56-0 5210
19
Losartan Approved Phase 4 114798-26-4 3961
20
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
21
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
22
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
23
Pantoprazole Approved Phase 4 102625-70-7 4679
24
Eplerenone Approved Phase 4 107724-20-9 150310 443872
25
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
26
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
27
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
28
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
29
tannic acid Approved Phase 4 1401-55-4
30
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
31
Ethanol Approved Phase 4 64-17-5 702
32
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
33
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
34
Promethazine Approved, Investigational Phase 4 60-87-7 4927
35
Testosterone Approved, Investigational Phase 4 58-22-0 6013
36
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
37
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
38
Zolpidem Approved Phase 4 82626-48-0 5732
39
Liraglutide Approved Phase 4 204656-20-2 44147092
40
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
41
Metformin Approved Phase 4 657-24-9 14219 4091
42
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
43
Carbidopa Approved Phase 4 28860-95-9 34359
44
Levodopa Approved Phase 4 59-92-7 6047
45
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
46
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
47
Finasteride Approved Phase 4 98319-26-7 57363
48
Buspirone Approved, Investigational Phase 4 36505-84-7 2477
49
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
50
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3

Interventional clinical trials:

(show top 50) (show all 2079)
# Name Status NCT ID Phase Drugs
1 Comparison of the Pentax AWS® With the Macintosh Laryngoscope for Tracheal Intubation in Patients With Obstructive Sleep Apnea Syndrome: a Randomized Comparative Study Unknown status NCT01428570 Phase 4
2 Open, Prospective Study for the Validation of the Predictive Value of Upper Airway Segmentation and CFD Analysis on Outcome Parameters of the Mandibular Replacement Appliance (MRA) Therapy in Obstructive Sleep Apnea Hypopnea Syndrome OSAHS) Patients Unknown status NCT01524510 Phase 4
3 Cost-utility Study of CPAP Treatment in Obstructive Sleep Apnea Patients Unknown status NCT01590420 Phase 4
4 A Randomized Cross Over Trial of Two Treatments for Obstructive Sleep Apnea in Veterans With Post Traumatic Stress Disorder Unknown status NCT01535586 Phase 4
5 Donepezil Treatment for Sleep Apnea Patients: A Double Blind Placebo-Controlled Study Unknown status NCT00912457 Phase 4 donepezil;placebo
6 Effect of Treating Sleep Apnea With Oral Appliances in the Elderly: ORACLE Study Unknown status NCT02325089 Phase 4
7 Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea. A Double Blinded Placebo Controlled, Crossover Prospective Trial. Unknown status NCT02630121 Phase 4 Oxymetazoline Hydrochloride;Placebo
8 A Comparison Between Two Different Oral Appliance Therapies: Somnodent vs Herbst Appliance in Patients With Mild and Moderate OSA Unknown status NCT02724865 Phase 4
9 Effects of Continuous Positive Airway Pressure (CPAP) and Nebivolol Treatment on Arterial Blood Pressure and Endothelial Function in Hypertensive OSA Patients. Unknown status NCT01771406 Phase 4 Nebivolol
10 Randomised Monocentric -Controlled Study to Evaluate the Efficacy and Stability of Dexmedetomidine Sedation Compared to Propofol Sedation in the Routinely Diagnostic Examination: Drug Induced Sleep Endoscopy Unknown status NCT03892122 Phase 4 Propofol Fresenius;Dexmedetomidine
11 The Effect of Nasal CPAP in Patients With Chronic Fatigue and Sleep-disordered Breathing Unknown status NCT01368718 Phase 4
12 Blood Pressure Reduction Induced by Continuous Positive Airway Pressure (CPAP) in Sleep Apnea Patients at High Cardiovascular Risk : A Randomized Controlled Trial Comparing Usual CPAP Care Versus a Multidisciplinary and Coordinated Follow-up Based on a Telemonitoring Web Platform Unknown status NCT01505959 Phase 4
13 Effects of the Continuous Positive Airway Pressure Ventilation on the Prevalence of the Metabolic Syndrome and Cardiac Morpho-Functional Characteristics in Sleep Apnea Syndrome Unknown status NCT00517777 Phase 4
14 Multidisciplinary and Coordinated Follow-up Based on a Telemonitoring Web Platform for Improving Continuous Positive Airway Pressure (CPAP) Compliance in Low Cardiovascular Risk Sleep Apnea Patients Unknown status NCT01796769 Phase 4
15 Sleep Disordered Breathing in TIA/Ischemic Stroke: Effects on Short- and Long-term Outcome and CPAP Treatment Efficacy: an Open, Observational, Clinical, Multicentre Trial With a Randomized Arm Unknown status NCT01097967 Phase 4
16 Adaptative Servoventilation Compliance in Left Ventricular Dysfunction Patients With Central Sleep Apnea: Benefit of One Month Hypnotic (Zopiclone) Versus Placebo Unknown status NCT02820441 Phase 4 Zopiclone;Placebo
17 Effect of Acetazolamide on Central Sleep Apnea Related to Opium Consumption Unknown status NCT02371473 Phase 4 Acetazolamide-placebo;Placebo-acetazolamide
18 Effect of Servo-Ventilation on CO2 Regulation and Heart Rate Variability Unknown status NCT03890939 Phase 4
19 Inflammatory Response to Anti Inflammatory Therapy in Children With Sleep Disordered Breathing Unknown status NCT00299910 Phase 4 Montelukast
20 Donepezil for Residual Symptoms in CPAP Treated Obstructive Sleepapnea Patients: A Controlled Study Unknown status NCT03299257 Phase 4 donepezil treatment
21 Efficacy of Oral Leukotriene in Long Term Therapy of Mild and Moderate Obstructive Sleep Apnea Syndrome (OSAS) in Children Completed NCT00912171 Phase 4 budesonide (Aircort 50 nasal spray);montelukast (Singulair)
22 Ketamine Infusion for Pediatric Patients With Obstructive Sleep Apnea Syndrome After Tonsillectomy: A Randomized Controlled Trial Completed NCT02425202 Phase 4 Ketamine
23 Comparative Study of Effect of Valsartan 160mg Treatment Versus Continuous Positive Airway Pressure on Arterial Blood Pressure in Patients Who Have an Obstructive Sleep Apnea Syndrome and a Weak or Moderate Hypertension. Completed NCT00409487 Phase 4 Valsartant treatment
24 Obstructive Sleep Apnea in the Absence of Metabolic Syndrome: Pulse Wave Velocity, Inflammatory and Oxidative Stress Markers Completed NCT01635010 Phase 4
25 Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea Completed NCT01181570 Phase 4 Adalimumab;Placebo
26 Sugammadex Compared With Neostigmin/Atropin for Neuromuscular Block Reversal in Patients With Obstructive Sleep Apnea Completed NCT02160223 Phase 4 Sugammadex;Neostigmine
27 Effects of Continuous Positive Airway Pressure (CPAP) on Early Signs of Atherosclerosis in Patients With Obstructive Sleep Apnea: a Randomized Study Completed NCT00400543 Phase 4
28 Mechanism of Action of Fluticasone Furoate in Childhood Obstructive Sleep Apnea Syndrome Completed NCT00603044 Phase 4 fluticasone furoate
29 Efficacy of Continuous Positive Airway Pressure (CPAP) on Blood Pressure Control of Resistant Hypertension Patients With Obstructive Sleep Apnea Syndrome (OSAS). Completed NCT01508754 Phase 4
30 Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome With Major Depressive Disorder or Dysthymic Disorder Completed NCT00518986 Phase 4 armodafinil;placebo
31 Phase 4 Study of the Relationship Between the Oxidative Stress and the Development of Cardiovascular Complications in the Sleep Apnea-hypopnea Syndrome (SAHS). Effect of the Treatment With CPAP Completed NCT00487929 Phase 4
32 The Endothelium Dysfunction in Patients of Obstructive Sleep Apnea Syndrome Completed NCT01699126 Phase 4 Statin
33 Sleep Apnea-hypopnea Syndrome and Ventricular Arrhythmias in Patients With Systolic Ventricular Dysfunction and Implantable Cardioverter-defibrillator. Incidence and Effect of CPAP Treatment Completed NCT00765713 Phase 4
34 Differential Effects of Chronic Treatment of OSAS by CPAP and SOMNOsmart2 on Norepinephrine and Blood Pressure Completed NCT00633711 Phase 4
35 Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00714740 Phase 4 acetazolamide
36 Does Nasal Decongestion Improve Obstructive Sleep Apnea ? Completed NCT00630474 Phase 4 xylometazoline
37 PROMAD : Predicting Therapeutic Outcome of Mandibular Advancement Device Treatment in Obstructive Sleep Apnea Completed NCT01532050 Phase 4
38 Continuous Positive Airway Pressure (CPAP) and Acetazolamide for Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00928655 Phase 4 acetazolamide;placebo
39 Randomized, Placebo-Controlled Multicenter Trial of the Effects of Orally Administered Xyrem (Sodium Oxybate) and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients Completed NCT00086281 Phase 4 Xyrem (X);Zolpidem (Z);Modafinil (M);Placebo (P)
40 Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome Completed NCT00560586 Phase 4 Budesonide;placebo
41 Respiratory Impact of Short Life Agents Used in Balanced Anesthesia on Patients Suffering or Suspected of Obstructive Sleep Apnea (OSA) Syndrome Completed NCT02717780 Phase 4 Fentanyl and sevoflurane;Remifentanil and desflurane
42 Randomized, Double-blind Study to Compare Safety and Effectiveness of the ProventTM Professional Sleep Apnea Therapy Device to Sham for the Non-invasive Treatment of OSAH Completed NCT00772044 Phase 4
43 A Placebo Controlled Double Blinded Crossover Study of the Antihypertensive Efficacy of Guanfacine vs Hydrochlorothiazide in Obstructive Sleep Apnea (OSA) Associated Hypertension Completed NCT02699125 Phase 4 Guanfacine;Hydrochlorothiazide
44 SASQT: SensAwake™ Sleep Quality Trial A Study to Test the Efficacy of the SensAwake™ Modification to Automatically Titrating Continuous Positive Airway Pressure to Reduce Wake After Sleep Onset in Patients With Moderate to Severe Obstructive Sleep Apnea. Completed NCT00811213 Phase 4
45 Effect of Increasing Depth of Dexmedetomidine and Propofol Anesthesia on Upper Airway Morphology in Children With History of Obstructive Sleep Apnea Completed NCT01344759 Phase 4 Dexmedetomidine;Propofol
46 Impact of Obstructive Sleep Apnea Treatment in Patients With Metabolic Syndrome: A Randomized Study Completed NCT02295202 Phase 4
47 The Effect of Trazodone on the Severity of Obstructive Sleep Apnea in Insomnic Stroke Patients With Depression Completed NCT04162743 Phase 4 Trazodone;Placebo oral tablet
48 The Impact of Venlafaxine on Apnea Hypopnea Index in Patients With Obstructive Sleep Apnea Completed NCT02714400 Phase 4 Venlafaxine;Placebo
49 Prospective, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Effect of Eszoplicone on Initial Continuous Positive Airway Pressure (CPAP) Compliance Completed NCT00612157 Phase 4 Eszopiclone;Placebo control
50 Efficacy of Sibutramine-induced Weight Loss vs. Continuous Positive Airway Pressure (CPAP) in the Treatment of Obese Patients With Obstructive Sleep Apnea Completed NCT00729963 Phase 4 Sibutramine

Search NIH Clinical Center for Apnea, Obstructive Sleep

Cochrane evidence based reviews: sleep apnea, obstructive

Genetic Tests for Apnea, Obstructive Sleep

Genetic tests related to Apnea, Obstructive Sleep:

# Genetic test Affiliating Genes
1 Obstructive Sleep Apnea Syndrome 29

Anatomical Context for Apnea, Obstructive Sleep

MalaCards organs/tissues related to Apnea, Obstructive Sleep:

40
Heart, Endothelial, Tongue, Liver, Bone, Lung, Kidney

Publications for Apnea, Obstructive Sleep

Articles related to Apnea, Obstructive Sleep:

(show top 50) (show all 5351)
# Title Authors PMID Year
1
Familial aggregates in obstructive sleep apnea syndrome. 61 57
7781344 1995
2
Atrial flutter associated with obstructive sleep apnea syndrome. A case report. 61 57
7352787 1980
3
APOE epsilon 4 allele, cognitive dysfunction, and obstructive sleep apnea in children. 57
17636061 2007
4
Nocturnal sleep apnea/hypopnea is associated with lower memory performance in APOE epsilon4 carriers. 57
16116137 2005
5
APOE epsilon4 is associated with obstructive sleep apnea/hypopnea: the Sleep Heart Health Study. 57
15326239 2004
6
Serum amyloid a in obstructive sleep apnea. 57
12952844 2003
7
A whole-genome scan for obstructive sleep apnea and obesity. 57
12506338 2003
8
Association between sleep apnea syndrome and nonarteritic anterior ischemic optic neuropathy. 57
12003609 2002
9
Association between apolipoprotein E epsilon4 and sleep-disordered breathing in adults. 57
11401610 2001
10
The genetics of sleep apnea. 57
12531037 2000
11
Familial predisposition to snoring. 57
8153952 1994
12
Is the sleep apnoea/hypopnoea syndrome inherited? 57
8153920 1993
13
Studies in the genetics of obstructive sleep apnea. Familial aggregation of symptoms associated with sleep-related breathing disturbances. 57
1736754 1992
14
Familial 'sleep apnea plus' syndrome: report of a family. 57
3257550 1988
15
Sleeping and breathing. 57
692617 1978
16
Obstructive sleep apnea in family members. 57
211413 1978
17
The sleep apnea syndromes. 57
180875 1976
18
Plasma adiponectin level and sleep structures in children with Prader-Willi syndrome. 61 54
19912511 2010
19
Association of sleep apnea severity and obesity with insulin resistance, C-reactive protein, and leptin levels in male patients with obstructive sleep apnea. 61 54
18365276 2008
20
Re: Leptin and leptin receptor gene polymorphisms in obstructive sleep apnea syndrome. 54 61
18574304 2008
21
Leptin and leptin receptor gene polymorphisms in obstructive sleep apnea syndrome. 61 54
17989154 2008
22
Serum levels of adipocytokines, adiponectin and leptin, in patients with obstructive sleep apnea syndrome. 61 54
18981626 2008
23
Leptin measurement in urine is a reliable method of monitoring its secretion in patients with obstructive sleep apnea syndrome. 61 54
18204121 2007
24
Frequency of distribution of leptin receptor gene polymorphism in obstructive sleep apnea patients. 61 54
18204169 2007
25
Reduced levels of adiponectin in sleep apnea syndrome. 61 54
17033258 2006
26
[The influence of 3 weeks therapy with continuous positive airway pressure on serum leptin and homocysteine concentration in patients with obstructive sleep apnea syndrome]. 54 61
17175979 2006
27
Leptin and ghrelin levels in patients with obstructive sleep apnea syndrome. 61 54
16088283 2005
28
Neuropeptide Y and leptin in patients with obstructive sleep apnea syndrome: role of obesity. 54 61
15516536 2005
29
Adiponectin in patients with obstructive sleep apnea syndrome: course and physiological relevance. 54 61
15627868 2004
30
Decreased plasma levels of orexin-A in sleep apnea. 54 61
15627867 2004
31
The association of the severity of obstructive sleep apnea with plasma leptin levels. 54 61
12759266 2003
32
Changes in intra-abdominal visceral fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy. 61 54
10449691 1999
33
The prevalence of sleep impairments and predictors of sleep quality among patients with asthma. 61
31903810 2021
34
Topical Triamcinolone on "Sweet Spots" to Block Dynamic Pain after Tonsillectomy and Uvulo-Palato-Pharyngo-Plasty. 61
32909450 2021
35
Perceptual snoring as a basis for a psychoacoustical modeling and clinical patient profiling. 61
33797031 2021
36
Use of mandibular advancement devices for the treatment of primary snoring with or without obstructive sleep apnea (OSA): A systematic review. 61
33326914 2021
37
[Obstructive sleep apnea syndrome in children]. 61
33730248 2021
38
Home respiratory polygraphy in obstructive sleep apnea syndrome in children: Comparison with a screening questionnaire. 61
33535090 2021
39
Evaluation of facial soft tissues by stereophotogrammetry method in patients with obstructive sleep apnea: a morphological study. 61
33778939 2021
40
A deep cascaded segmentation of obstructive sleep apnea-relevant organs from sagittal spine MRI. 61
33770362 2021
41
Normal values for respiratory sleep polygraphy in children aged 4 to 9 years at 2,560 m above sea level. 61
33723892 2021
42
Short-term intermittent hypoxia induces simultaneous systemic insulin resistance and higher cardiac contractility in lean mice. 61
33682327 2021
43
The relationship between extracellular fluid and obstructive sleep apnea in non-obese patients. 61
33689596 2021
44
Dramatic impact of morbid obesity on child lung development. 61
33714673 2021
45
Factors determining the long-term compliance with PAP therapy in patients with sleep-related epilepsy. 61
33476884 2021
46
Practical and rapidly-implemented parameters for assessing APAP titration failure. 61
32193843 2021
47
Orthostatic Intolerance after Bariatric Surgery: a Systematic Review. 61
33655427 2021
48
Risk Factors for Postoperative Bleeding after Adenoidectomy. 61
33801025 2021
49
[Sleep characteristics of a population of patients seeking bariatric surgery]. 61
33775490 2021
50
Effectiveness of functional orthodontic appliances in obstructive sleep apnea treatment in children: literature review. 61
33757756 2021

Variations for Apnea, Obstructive Sleep

ClinVar genetic disease variations for Apnea, Obstructive Sleep:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 RYR1 NM_000540.2(RYR1):c.10097G>T (p.Arg3366Leu) SNV Uncertain significance 598974 rs137932199 GRCh37: 19:39009932-39009932
GRCh38: 19:38519292-38519292
2 SYNE2 NM_182914.2(SYNE2):c.19624G>T (p.Gly6542Trp) SNV Uncertain significance 598975 rs746433383 GRCh37: 14:64685197-64685197
GRCh38: 14:64218479-64218479

Expression for Apnea, Obstructive Sleep

Search GEO for disease gene expression data for Apnea, Obstructive Sleep.

Pathways for Apnea, Obstructive Sleep

Pathways related to Apnea, Obstructive Sleep according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.2 TNF LEP INS IL6 IGF1 HTR2A
2
Show member pathways
13.36 TNF REN LEP INS IL6 IL1B
3
Show member pathways
13.06 REN INS IL6 IGF1 HIF1A AGT
4 12.86 IL6 IGF1 HIF1A EDN1 CXCL8 AGT
5
Show member pathways
12.79 TNF LEP INS IL6 ADIPOQ
6
Show member pathways
12.34 TNF IL6 IL1B CXCL8
8
Show member pathways
12.29 TNF IL6 IL1B IGF1 CXCL8
9 12.26 TNF IL6 IL1B CXCL8
10
Show member pathways
12.25 TNF IL6 IL1B EDN1 CXCL8
11
Show member pathways
12.22 TNF IL6 IGF1 EDN1 AGT ACE
12
Show member pathways
12.21 TNF IL6 IL1B CXCL8
13
Show member pathways
12.2 TNF INS IL6 IL1B CRP APOE
14
Show member pathways
12.19 TNF IGF1 EDN1 AGT
15 12.12 TNF IL6 IL1B HTR2A HIF1A CXCL8
16 12.11 TNF IL6 IL1B CXCL8
17 12.09 INS IL6 IGF1 ALB
18 12.04 TNF LEP IL6 IL1B CXCL8
19 12.01 TNF IL6 IL1B HIF1A CXCL8
20 12 TNF IL6 IL1B EDN1
21
Show member pathways
11.98 TNF INS IL6 AGT
22 11.98 INS IL6 IGF1 HIF1A EDN1
23 11.96 INS IL6 IL1B IGF1 CXCL8
24
Show member pathways
11.96 REN LEP INS IGF1 GHRL AGT
25 11.95 TNF IL6 IL1B CXCL8
26 11.9 TNF IL6 IL1B CXCL8
27 11.89 LEP INS IL6 IGF1 ADIPOQ
28 11.8 TNF IL6 IL1B CXCL8
29
Show member pathways
11.77 TNF IL6 IL1B
30 11.76 TNF IL6 IL1B
31 11.75 REN EDN1 AGT ACE
32 11.73 TNF IL6 IL1B EDN1 CXCL8 AGT
33 11.72 TNF LEP ADIPOQ
34
Show member pathways
11.7 TNF IL6 IL1B CXCL8
35 11.69 LEP HIF1A EDN1
36 11.65 TNF IL6 IL1B CXCL8
37